Alamar Biosciences, Inc. is a commercial-stage proteomics company specializing in advanced protein detection and analysis technologies. It develops and commercializes the proprietary NULISA platform, designed to overcome limitations of traditional proteomics tools by enabling detection of protein biomarkers at extremely low concentrations in non-invasive biological fluids like blood. Key features include ultra-high sensitivity, high specificity, flexible multiplexing capabilities, broad dynamic range, and seamless automation, establishing a gold standard for precision proteomics. The company serves the healthcare sector, particularly the medical devices industry, by providing tools for disease detection research, including early identification of cancer and other diseases through protein biomarker platforms. Alamar Biosciences, Inc. focuses on powering precision medicine applications in research and diagnostics. Founded in 2018 and headquartered in Fremont, California, it plays a significant role in advancing proteomics for biological and clinical research.